High population immunity from prior infections and updated vaccines has kept SARS-CoV-2 evolution within the Omicron lineage, with current subvariants such as XFG.1.1 circulating at low levels and producing no widespread surges in hospitalizations. The World Health Organization has not designated any new variant of concern since JN.1 in late 2023, reflecting the elevated bar for that classification—requiring clear evidence of substantially increased transmissibility, severity, or immune escape that meaningfully affects public health. Recent monitoring of the highly mutated BA.3.2 lineage shows modest spread in parts of Europe and limited U.S. detections without triggering emergency thresholds or exponential growth. Ongoing genomic surveillance and stable epidemiological indicators reinforce trader consensus that a new designation remains improbable through the end of 2026.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日はい
$238,975 Vol.
$238,975 Vol.
はい
$238,975 Vol.
$238,975 Vol.
The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
マーケット開始日： Dec 1, 2025, 4:49 PM ET
Resolver
0x65070BE91...The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Resolver
0x65070BE91...High population immunity from prior infections and updated vaccines has kept SARS-CoV-2 evolution within the Omicron lineage, with current subvariants such as XFG.1.1 circulating at low levels and producing no widespread surges in hospitalizations. The World Health Organization has not designated any new variant of concern since JN.1 in late 2023, reflecting the elevated bar for that classification—requiring clear evidence of substantially increased transmissibility, severity, or immune escape that meaningfully affects public health. Recent monitoring of the highly mutated BA.3.2 lineage shows modest spread in parts of Europe and limited U.S. detections without triggering emergency thresholds or exponential growth. Ongoing genomic surveillance and stable epidemiological indicators reinforce trader consensus that a new designation remains improbable through the end of 2026.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日
外部リンクに注意してください。
外部リンクに注意してください。
よくある質問